ProANP as a screening biomarker for hypertrophic cardiomyopathy in Maine coon cats

• Autorzy: Parzeniecka-Jaworska M. , Garncarz M. , Klucinski W.
• Języki publikacji: EN

Abstrakty

EN

The aim of this study was to determine if atrial natriuretic peptide can be used as an early screening tool for hypertrophic cardiomyopathy in Maine coon cats. Animals: The study was performed in 43 Maine coon cats of both sexes, aged 11 to 92 months. Clinical and echocardiographic examinations were done and proANP serum concentrations were measured every three months over a period of one year (each cat had a total of five examinations). Cats were divided into 3 groups based on echocardiographic results: group 1 – healthy cats, group 2 – cats with unequivocal hypertrophic cardiomyopathy results, group 3 – cats with HCM. The study showed that the concentration of atrial natriuretic peptide correlates with the severity of HCM. A significant increase in serum concentration of this peptide was observed in cats from group 3, but it did not differ significantly between cats from group 2 and the healthy animals (p>0.05). A correlation was also found between proANP and age of the cats (p<0.01, r=0.5578) as well as between the ejection fraction (p=0.0285, r=0.5305) and end-systolic left ventricular diameter (p=0.05, r=0.48) in the affected animals. Atrial natriuretic peptide may be used to help in the diagnosis of advanced stages of HCM in Maine coon cats. Cats with high levels of proANP should be assigned to echocardiographic studies to confirm the disease.

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2016
• Tom: 19
• Numer: 4
• Opis fizyczny: p.801-807,fig.,ref.

Twórcy

autor

Parzeniecka-Jaworska M.

• Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, Warsaw, Poland

autor

Garncarz M.

• Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, Warsaw, Poland

autor

Klucinski W.

• Department of Pathology and Veterinary Diagnostics, Faculty of Veterinary Medicine, Warsaw University of Life Sciences, Nowoursynowska 159c, Warsaw, Poland

Bibliografia

• Berger R, Huelsmann M, Strecker K, Moertl D, Moser P, Bojic A, Packer R (2005) Neurohormonal risk stratification for sudden death and heath owing to progressive heart failure in chronic heart failure. Eur J Clin Invest 35: 24-31.
• Borgeat K, Connolly DJ, Luis Fuentes V (2015) Cardiac biomarkers in cats. J Vet Cardiol 17 (Suppl 1): 74-86.
• Boswood A (2009) Biomarkers in cardiovascular disease beyond natriuretic peptides. J Vet Cardiol 11: 23-32.
• Chetboul V, Sampedrano CC, Gouni V, Nicolle AP, Pouchelon JL (2006) Two-dimensional color tissue Doppler imaging detects myocardial dysfunction before occurrence of hypertrophy in a young Maine Coon cat. Vet Radiol Ultrasound 47: 295-300.
• Connolly DJ, Soares Magalhaes RJ, Syme HM, Boswood A, Luis Fuentes V, Chu L, Metcalf M (2008) Circulating natriuretic peptides in cats with heart disease. J Vet Intern Med 22: 96-105.
• Connolly DJ, Soares Magalhaes RJ, Fuentes VL, Boswood A, Cole G, Boag A, Syme HM (2009) Assessment of the diagnostic accuracy of circulating natriuretic peptide concentrations to distinguish between cats with cardiac and non-cardiac causes of respiratory distress. J Vet Cardiol 11 (Suppl 1): 41-50.
• Connolly DJ (2010) Natriuretic peptides: the feline experience. Vet Clin North Am Small Anim Pract 40: 559-570.
• Gough A, Thomas A (2004) Disease summaries. In: Gough A, Thomas A (eds) Breed predispositions to disease in dogs and cats. 2ed., Wiley Blackwell, Iowa, pp 229-230.
• Hall C, Ihlen H, Bonarjee V, Dickstein K, Kjekshus J (2003) N-terminal proatrial natriuretic peptide in primary care: relation to echocardiographic indices of cardiac function in mild to moderate cardiac disease. Int J Cardiol 89: 197-205.
• Jandrey K (2012) Thromboembolism: current treatment and future directions. Veterinary Focus 22: 26-31.
• Jarai R, Iordanowa N, Jarai R, Raffetseder A, Woloszczuk W, Gyöngyösi M, Geyer G, Wojta J, Huber K (2005) Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur Heart J 26: 250-256.
• Kittleson M, (1998) Hypertrophic Cardiomyopathy. In: Kittleson M, Kienle R (eds) Small Animal Cardiovascular Medicine. Mosby Inc, St. Louis, pp 347-360.
• Kittleson MD, Meurs KM, Munro MJ, Kittleson JA, Si-Kwang L, Pion PD, Towbin JA (1999) Familial hypertrophic cardiomyopathy in maine coon cats: an animal model of human disease. Circulation 99: 3172-3180.
• Kołodziejska A, Kander M, Depta A, Szweda M (2010) Structure, mechanism of action and the significance of natriuretic peptides in the diagnosis of heart disease in dogs. Życie Weterynryjne 85: 825-829.
• Lalor SM, Connolly DJ, Elliott J, Syme HM (2009) Plasma concentrations of natriuretic peptides in normal cats and normotensive and hypertensive cats with chronic kidney disesase. J Vet Cardiol 11 (Supp1): 71-79.
• MacLean HN, Abbott JA, Ward DJ, Huckle WR, Sisson DD, Pyle RL (2006) N- terminal atrial natriuretic peptide immunoreactivity in plasma of cats with hypertrophic cardiomyopathy. J Vet Intern Med 20: 284-289.
• Menaut P, Connolly DJ, Volk A, Pace C, Luis Fuentes V, Elliott J, Syme H (2012) Circulating natriuretic peptide concentrations in hyperthyroid cats. J Small Anim Pract 53: 673-678.
• Meurs KM, Norgard MM, Kuan M, Haggström J, Kittleson M (2009) Analysis of 8 sarcomeric candidate genes for feline hypertrophic cardiomyopathy mutations in cats with hypertrophic cardiomyopathy. J Vet Intern Med 23: 840-843.
• Müller E (2006) Laboratory diagnostics in heart diseases. Weterynaria w praktyce 6: 77-79.
• Otterstad JE, St John Sutton MG, Froeland GS, Holme I, Skjaerpe T, Hall C (2002) Prognostic value of two-dimensional echocardiography and N-terminal proatrial natriuretic peptide following an acute myocardial infarction. Eur Heart J 23: 1011-1020.
• Pasławska U (2006) Neurohormonal changes in dogs with heart failure secondary to chronic mitral valvedisease. Doctoral Thesis, Wrocław Agricultural Academy.
• Sampedrano C, Chetboul V, Mary J, Tissier R, Abitbol M, Serres F, Gouni V, Thomas A, Pouchelon JL (2009) Prospective echocardiographic and tissue Doppler imaging screening of a population of Maine Coon cats tested for the A31P mutation in the myosin-binding protein C gene: a specific analysis of the heterozygous status. J Vet Intern Med 23: 91-99.
• Trehion-Sechi E, Tissier R, Gouni V, Misbach C, Petit AM, Balouka D, Sampedrano CC, Castaignet M, Pouchelon JL, Chetboul V (2012) Comparative echocardiographic and clinical features of hypertrophic cardiomyopathy in 5 breeds of cats: a retrospective analysis of 344 cases (2001-2011). J Vet Intern Med 26: 532-541.
• Ware WA (2007) Myocardial diseases of the cat. In: Ware WA (ed) Cardiovascular disease in small animal medicine. Manson Publishing, London, pp 300-308.
• Zimmering TM, Meneses F, Nolte IJ, Simon D (2009) Measurement of N-terminal proatrial natriuretic peptide in plasma of cats with and without cardiomyopathy. Am J Vet Res 70: 216-222.
• Zimmering TM, Hungerbu¨hler S, Meneses F, Nolte I, Simon D (2010) Evaluation of the association between plasma concentration of N-terminal proatrial natriuretic peptide and outcome in cats with cardiomyopathy. J Am Vet Med Assoc 237: 665-672.

Identyfikatory

DOI

10.1515/pjvs-2016-0101